拉米夫定联合苦参素治疗慢性乙型肝炎疗效观察

目的探讨拉米夫定联合苦参素治疗慢性乙型肝炎的效果。方法将研究对象随机分为联合治疗组和拉米夫定组。联合治疗组给予拉米夫定100 mg/d口服,疗程12个月;于开始用拉米夫定治疗时联合苦参素,600 mg/次,静脉注射,1次/d,连续2个月。拉米夫定组仅给予拉米夫定100 mg/d口服,疗程12个月。于治疗开始后第1,3,6,9,12个月及随访期第3,6,12个月进行临床评估及实验室检查。结果联合治疗组肝功能恢复明显,治疗开始后6,12个月和随访6,12个月时HBeAg/抗HBe血清转换率分别为48.28%,51.72%,51.72%,48.28%;拉米夫定组分别为6.45%,9.68%,9.68%,9.68%;两组比较,差异均有显著性(P=0.001)。结论拉米夫定联合苦参素具有协同抗HBV效应,能明显改善慢性乙型肝炎患者临床生化指标。

Curative effect of lamivudine combined oxymatrine for patients with hepatitis B

Objective To evaluate the curative effect of lamivudine combined oxymatrine for patients with hepatitis B.Methods The study subjects were randomly divided into lamivudine combined oxymatrine treatment group and lamivudine group.Patients in combined group were given lamivudine 100 mg/day orally for 12 months,at the beginning of lamivudine treatment,oxymatrine was also given 600mg intravenously once a day for consecutive 2 months.In lamivudine group,patients were only given lamivudine 100 mg/day orally for 12 months.Clinical evaluation and laboratory detection were performed at the 1,3,6,9,12 months of treatment and 3,6,12 months of the follow up period.Results In combined group,liver function improved rapidly,the seroconversion rate of HBeAg/anti-HBe at the 6th,12th month of the treatment period and 6th,12th month of the follow up period was 48.28%,51.72%,51.72% and 48.28% respectively;while in lamivudine group,seroconversion rate of HBeAg/anti-HBe was 6.45%,9.68%,9.68% and 9.68% respectively,there was significant difference between two groups(P=(0.001)).Conclusion lamivudine combined oxymatrine had synergistic treatment efficacy for treating HBV.